Literature DB >> 1083738

Estimation of plasma esterolytic activity and its in vitro inhibition by proteinase inhibitors during acute pancreatitis in the human.

K J Worthington, A Cuschieri.   

Abstract

The plasma esterolytic activity was measured using benzyol arginine ethyl ester (BAEe) in the peripheral venous blood of patients with acute pancreatitis, normal healthy volunteers and a contrast group of patients with acute intrabdominal inflammations other than acute pancreatitis. The plasma esterolytic activity was significantly elevated in the pancreatitis group. This activity was maximal during the first 48 hours of the illness and remained elevated for a further 8 days thereafter. Aprotinin in a dose of 2000 K.I. u/0-3 ml plasma did not completely inhibit this esterolytic activity, although it resulted in a more substantial inhibition than either ovomucoid or soy bean inhibitor. It is concluded that pancreatic enzymes are released into the circulation during acute pancreatitis and that Aprotinin does not completely inhibit this proteolytic activity. This polyvalent proteinase inhibitor should therefore be administered in much higher dosage than that used hitherto in acute pancreatitis. The plasma esterolytic activity seems to be of diagnostic value in acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1083738      PMCID: PMC2041106     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  17 in total

1.  Therapy with kallikrein and protease inhibitors.

Authors:  M M FORELL
Journal:  Ann N Y Acad Sci       Date:  1963-02-04       Impact factor: 5.691

2.  [Experimental data on the efficacy of the kallikrein-trypsin inactivator (Trasylol)].

Authors:  M GUELZOW; H J TRETTIN; K DIWOK
Journal:  Klin Wochenschr       Date:  1961-06-01

3.  Acute pancreatitis; analysis of 100 patients.

Authors:  A V POLLOCK
Journal:  Br Med J       Date:  1959-01-03

4.  Use of crystalline soybean trypsin inhibitor in acute hemorrhagic pancreatitis in dogs.

Authors:  H L HOFFMAN; J JACOBS; S O FREEDLANDER
Journal:  AMA Arch Surg       Date:  1953-05

5.  A controlled trial of Trasylol in the treatment of acute pancreatitis.

Authors:  J E Trapnell; C C Rigby; C H Talbot; E H Duncan
Journal:  Br J Surg       Date:  1974-03       Impact factor: 6.939

6.  Proteinase inhibitors in experimental and clinical pancreatitis.

Authors:  A G Thompson
Journal:  Ann N Y Acad Sci       Date:  1968-06-28       Impact factor: 5.691

7.  Trasylol in acute pancreatitis.

Authors:  J E Trapnell; C H Talbot; W M Capper
Journal:  Am J Dig Dis       Date:  1967-04

8.  Diagnosis and management of acute pancreatitis.

Authors:  P Stefanini; M Ermini; M Carboni
Journal:  Am J Surg       Date:  1965-12       Impact factor: 2.565

9.  A study on the kinetics of pancreatic kallikrein with the substrate benzoyl arginine ethyl ester using a spectrophotometric assay.

Authors:  K J Worthington; A Cuschieri
Journal:  Clin Chim Acta       Date:  1974-04       Impact factor: 3.786

10.  A prospective study of acute pancreatitis.

Authors:  C W Imrie; A S Whyte
Journal:  Br J Surg       Date:  1975-06       Impact factor: 6.939

View more
  5 in total

1.  Impaired mononuclear phagocyte function in patients with severe acute pancreatitis: evidence from studies of plasma clearance of trypsin and monocyte phagocytosis.

Authors:  M Larvin; D J Alexander; S F Switala; M J McMahon
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

2.  Activation and release of proteolytic kinin-forming enzymes from rat jejunal loops perfused with hyperosmolar glucose solutions.

Authors:  K J Worthington; A Cuschieri
Journal:  Gut       Date:  1977-04       Impact factor: 23.059

3.  Immunoreactive forms of cationic trypsin in plasma and ascitic fluid of dogs in experimental pancreatitis.

Authors:  M C Geokas; C Largman; P R Durie; J W Brodrick; S B Ray; M O'Rourke; J Vollmer
Journal:  Am J Pathol       Date:  1981-10       Impact factor: 4.307

4.  Antiproteinase chemotherapy of acute experimental pancreatitis using the low molecular weight oligopeptide aldehyde leupeptin.

Authors:  P A Jones; J Hermon-Taylor; D A Grant
Journal:  Gut       Date:  1982-11       Impact factor: 23.059

5.  Collagenase inhibition in the healing colon.

Authors:  H L Young; M H Wheeler
Journal:  J R Soc Med       Date:  1983-01       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.